peaks during dose escalation, typically mild-moderate Diarrhea -- 10-20%, usually transient Constipation -- 8-15% Vomiting -- 5-15%, more frequent at higher doses Injection site reactions -- 5-10%, mild erythema and pruritus Decreased appetite -- 5-12%, related to mechanism of action Pancreatitis -- rare but monitored (as with all GLP-1/amylin agents) Gallbladder events -- cholelithiasis reported, consistent with rapid weight loss Trial data describes dose titration as central to tolerability -- the 16-week escalation protocol substantially reduced GI adverse events
Methylcobalamin 1500 mcg Uses Common uses of this injection include: This injection improves the low levels of vitamin B12 caused by poor diet, malabsorption, or higher physiological demand
GHK-Cu is a peptide that naturally exists in the human body
241 GLP-1(936) retains its ability to inhibit glucagon secretion even after GLP-1R inactivation, suggesting that its mechanism of action may not be entirely dependent on the GLP-1R
Drug Categories Amino Acids, Peptides, and Proteins Additional Notes Chemically stable in gastric juice (?24 hours) Water-soluble at neutral pH Not approved for human or veterinary use Summary Table Disclaimer For Research Use Only